Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
setanaxib
- Development stage
- Phase 2
- Lead developer
- Calliditas Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Setanaxib (formerly GKT137831) is a first-in-class, orally bioavailable small molecule inhibitor of NADPH oxidase (NOX) isoforms 1 and 4. Originally developed by Genkyotex and subsequently acquired by Calliditas Therapeutics (now a subsidiary of Asahi Kasei), setanaxib targets the enzymatic production of reactive oxygen species (ROS) that drive pathological inflammation and fibrotic tissue remodeling. The drug is currently being evaluated in several Phase 2 and Phase 3 clinical trials for conditions such as primary biliary cholangitis (PBC), Alport syndrome, idiopathic pulmonary fibrosis (IPF), and diabetic kidney disease. In addition to its anti-fibrotic properties, setanaxib is being investigated in oncology for its potential to inhibit cancer-associated fibroblasts (CAFs), thereby enhancing the efficacy of immunotherapies in solid tumors.
- Brand names
- setanaxib
- Other names
- setanaxib
02
Targets
NOX4 (NADPH oxidase 4)XO (Xanthine Oxidoreductase)NOX1 (NADPH oxidase 1)
Beyond the preview
Go deeper on setanaxib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on setanaxib.